DGIdb - ERBB4 Gene Record

ERBB4 2066 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

2066
ERB-B2 RECEPTOR TYROSINE KINASE 4
ERBB4
ALS19
HER4
p180erbB4
600543
3432
ENSG00000178568
OTTHUMG00000133012
TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER4
Q15303
ERBB4 intracellular domain
Proto-oncogene-like protein c-ErbB-4
s80HER4
Receptor tyrosine-protein kinase erbB-4
4ICD
E4ICD
EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER4 (ERBB4)
1799
NM_001042599
NP_001036064
ERBB4_HUMAN
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 PRECURSOR (EC 2.7.1.112) (P180ERBB4) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER4). [SOURCE:UNIPROT/SWISSPROT;ACC:Q15303]
1734
BE0004772
PA27847

Gene Info:

GuideToPharmacology Gene Category Name	Type I RTKs: ErbB (epidermal growth factor) receptor family
GuideToPharmacology Gene Category ID	320
Human Readable Name	KINASE
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
Interpro Type	Domain
Uniprot Status	Swiss-Prot
Human Readable Name	DRUGGABLE GENOME
Interpro Acc	IPR001245
Uniprot Evidence	1: Evidence at protein level
Target Class	Receptors
Target Subclass	EC:2.7.10.1
Gene Biotype	PROTEIN_CODING

(22 More Sources)

Gene Categories: Category Details

KINASE
TYROSINE KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Wang D et al., 2015, Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia., Pharmacogenet Genomics
Nakamura et al., 2016, Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC., Mol. Cancer Ther.
Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.
Canfield et al., 2015, Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells., Cell Cycle
Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem
Tam CS et al., 2019, Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL., Blood
Guo Y et al., 2019, Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase., J Med Chem
Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

AC-480 ERBB4

Interaction Score: 1.73

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AC480

Novel drug target Novel Target

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology
DACOMITINIB ERBB4

Interaction Score: 1.66

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology MyCancerGenomeClinicalTrial
PELITINIB ERBB4

Interaction Score: 0.92

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome
POZIOTINIB ERBB4

Interaction Score: 0.83

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
ChemblInteractions GuideToPharmacology MyCancerGenomeClinicalTrial
METHYLCURCUMIN ERBB4

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25753330

Sources:
DTC
BMS-690514 ERBB4

Interaction Score: 0.59

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions
DIMETHYLCURCUMIN ERBB4

Interaction Score: 0.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25753330

Sources:
DTC
AFATINIB ERBB4

Interaction Score: 0.55

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Alteration ERBB4__.

Drug family ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen

combination therapy Lapatinib;Afatinib

PMIDs:
27207775

Sources:
DrugBank JAX-CKB CGI
CANERTINIB DIHYDROCHLORIDE ERBB4

Interaction Score: 0.46

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
AFATINIB DIMALEATE ERBB4

Interaction Score: 0.46

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
ALLITINIB ERBB4

Interaction Score: 0.46

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
LAPATINIB ERBB4

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status preclinical

PMIDs:
19718025 25590338

Sources:
DTC JAX-CKB CGI DoCM CIViC PharmGKB
OSIMERTINIB MESYLATE ERBB4

Interaction Score: 0.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
TUCATINIB ERBB4

Interaction Score: 0.35

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology
ZANUBRUTINIB ERBB4

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
31340982 31381333

Sources:
DrugBank
AEE-788 ERBB4

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology
JNJ-26483327 ERBB4

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
BRIGATINIB ERBB4

Interaction Score: 0.14

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
PALIPERIDONE ERBB4

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25714000

Sources:
PharmGKB
ERLOTINIB ERBB4

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27207775

Sources:
DTC JAX-CKB PharmGKB
ACALABRUTINIB ERBB4

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
AZD-1152-HQPA ERBB4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
GEFITINIB ERBB4

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DTC MyCancerGenomeClinicalTrial PharmGKB
IBRUTINIB ERBB4

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology
TAK-715 ERBB4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CETUXIMAB ERBB4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27207775

Sources:
JAX-CKB
CHEMBL578061 ERBB4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LAUROGUADINE ERBB4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SB-220025 ERBB4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CURCUMIN ERBB4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25753330

Sources:
DTC
ALISERTIB ERBB4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CEDIRANIB ERBB4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
VANDETANIB ERBB4

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
DASATINIB ERBB4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
R-406 ERBB4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RG-1530 ERBB4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SP-600125 ERBB4

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TAE-684 ERBB4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ILORASERTIB ERBB4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CENISERTIB ERBB4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FOSTAMATINIB ERBB4

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
26516587

Sources:
DrugBank

Ensembl: ENSG00000178568
- Version: 101_38
Alternate Names:

ERBB4 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

RussLampel: ENSG00000178568

Version: 26-July-2011

Alternate Names:

ENSG00000178568 Ensembl Gene Id

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 PRECURSOR (EC 2.7.1.112) (P180ERBB4) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER4). [SOURCE:UNIPROT/SWISSPROT;ACC:Q15303] Description

ERBB4 Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TdgClinicalTrial: Q15303
- Version: January-2014
Alternate Names:

ERBB4 Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass EC:2.7.10.1

Publications:
HopkinsGroom: Q15303
- Version: 11-September-2012
Alternate Names:

ERBB4_HUMAN Uniprot Id

2066 Entrez Gene Id

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 Uniprot Protein Name

Gene Info:

Human Readable Name KINASE

Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain

Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:
GuideToPharmacology: 2066
- Version: 29-September-2020
Alternate Names:

3432 HUGO Gene ID

3432 HUGO Gene Symbol

erb-b2 receptor tyrosine kinase 4 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name Type I RTKs: ErbB (epidermal growth factor) receptor family

GuideToPharmacology Gene Category ID 320

Publications:

JAX-CKB: ERBB4

Version: 27-September-2017

Alternate Names:

2066 CKB Entrez Id

ERBB4 CKB Gene Synonym

ALS19 CKB Gene Synonym

Gene Info:

Publications:

Nakamura et al., 2016, Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC., Mol. Cancer Ther.

Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.

PharmGKB: ERBB4
- Version: 18-August-2020
Alternate Names:

PA27847 PharmGKB ID

Gene Info:

Publications:

Wang D et al., 2015, Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia., Pharmacogenet Genomics

CIViC: ERBB4

Version: 14-September-2020

Alternate Names:

2066 Entrez Gene ID

1734 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.

Canfield et al., 2015, Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells., Cell Cycle

DrugBank: BE0004772

Version: 5.1.7

Alternate Names:

ERBB4 DrugBank Gene Name

Q15303 UniProt Accession

2066 Entrez Gene Id

Gene Info:

Publications:

Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

Guo Y et al., 2019, Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase., J Med Chem

Tam CS et al., 2019, Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL., Blood

DoCM: ERBB4
- Version: 27-September-2017
Alternate Names:

Gene Info:

Publications:

Prickett et al., 2009, Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4., Nat. Genet.
DTC: ERBB4
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:

Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem
TALC: HER4
- Version: 12-May-2016
Alternate Names:

HER4 Gene Symbol

Gene Info:

Publications:
HingoraniCasas: ENSG00000178568
- Version: 31-May-2017
Alternate Names:

ENSG00000178568 Gene Symbol

ERBB4 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: HER4
- Version: chembl_23
Alternate Names:

HER4 GENE_SYMBOL

ERBB4 GENE_SYMBOL

Receptor tyrosine-protein kinase erbB-4 UNIPROT

Gene Info:

Publications:
MyCancerGenome: ERBB4
- Version: 20-Jun-2017
Alternate Names:

2066 Entrez Gene Id

ERBB4 MyCancerGenome Gene Symbol

EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER4 (ERBB4) MyCancerGenome Reported Gene Name

Gene Info:

Publications:
Pharos: ERBB4
- Version: 03-September-2020
Alternate Names:

Receptor tyrosine-protein kinase erbB-4 Gene Name

Q15303 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
GO: ERBB4
- Version: 05-September-2020
Alternate Names:

HER4 GO Gene Synonym

Gene Info:

Gene Categories:

TYROSINE KINASE

Publications:
Tempus: ERBB4
- Version: 11-November-2018
Alternate Names:

ERBB4 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: ERBB4
- Version: 27-Jun-2013
Alternate Names:

2066 Gene ID

HER4 dGene Synonym

p180erbB4 dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
CGI: ERBB4
- Version: 27-September-2017
Alternate Names:

Gene Info:

Publications:
MskImpact: ERBB4
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
MyCancerGenomeClinicalTrial: ERBB4
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
ClearityFoundationClinicalTrial: ERBB4
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: ERBB4
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: ERBB4
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: ERBB4
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Trial Name	AC480
Novel drug target	Novel Target
Mechanism of Interaction	Receptor protein-tyrosine kinase erbB-4 inhibitor

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Notes
Mechanism of Interaction	Receptor protein-tyrosine kinase erbB-4 inhibitor
Direct Interaction	yes

Alteration	ERBB4__.
Drug family	ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen
combination therapy	Lapatinib;Afatinib

Variant Effect	gain-of-function
Pathway	activation
Clinical Status	preclinical

Mechanism of Interaction	Epidermal growth factor receptor inhibitor
Direct Interaction	yes

Indication/Tumor Type	head and neck squamous cell carcinoma
Response Type	resistant
Approval Status	Preclinical - Cell culture

ENSG00000178568	Ensembl Gene Id
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 PRECURSOR (EC 2.7.1.112) (P180ERBB4) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER4). [SOURCE:UNIPROT/SWISSPROT;ACC:Q15303]	Description
ERBB4	Display Id

ERBB4_HUMAN	Uniprot Id
2066	Entrez Gene Id
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4	Uniprot Protein Name

3432	HUGO Gene ID
3432	HUGO Gene Symbol
erb-b2 receptor tyrosine kinase 4	HUGO Gene Name

ERBB4	DrugBank Gene Name
Q15303	UniProt Accession
2066	Entrez Gene Id

HER4	GENE_SYMBOL
ERBB4	GENE_SYMBOL
Receptor tyrosine-protein kinase erbB-4	UNIPROT

Receptor tyrosine-protein kinase erbB-4	Gene Name
Q15303	UniProt ID

ERBB4 Gene Record

ERBB4 2066 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name AC480 Novel drug target Novel Target Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC MyCancerGenome

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: None found

Sources: ChemblInteractions GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25753330

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor Direct Interaction yes

PMIDs: None found

Sources: TALC MyCancerGenome ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25753330

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Alteration ERBB4__. Drug family ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen combination therapy Lapatinib;Afatinib

PMIDs: 27207775

Sources: DrugBank JAX-CKB CGI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info: Variant Effect gain-of-function Pathway activation Clinical Status preclinical

PMIDs: 19718025 25590338

Sources: DTC JAX-CKB CGI DoCM CIViC PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Epidermal growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 31340982 31381333

Sources: DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: None found

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AC480

Novel drug target Novel Target

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial ChemblInteractions GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
ChemblInteractions GuideToPharmacology MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
25753330

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
25753330

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Alteration ERBB4__.

Drug family ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen

combination therapy Lapatinib;Afatinib

PMIDs:
27207775

Sources:
DrugBank JAX-CKB CGI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status preclinical

PMIDs:
19718025 25590338

Sources:
DTC JAX-CKB CGI DoCM CIViC PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
31340982 31381333

Sources:
DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor protein-tyrosine kinase erbB-4 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
None found

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
25714000

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type head and neck squamous cell carcinoma

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27207775

Sources:
DTC JAX-CKB PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a